Dosage Regimen For Administering A Cd19Xcd3 Bispecific Antibody

Patent No. EP2493503 (titled "Dosage Regimen For Administering A Cd19Xcd3 Bispecific Antibody") was filed by Amgen Research Munich on Oct 27, 2010. The application was issued on Jan 20, 2021.

Patent Summary

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
AFFIMED GMBHMay 12, 2016SCHMITZ, GEORG

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP2493503

AMGEN RESEARCH MUNICH
Application Number
EP10771102A
Filing Date
Oct 27, 2010
Status
Patent Maintained As Amended
Dec 18, 2020
Publication Date
Jan 20, 2021